Get started
Zomedica Corp.Zomedica Corp.Zomedica Corp.

Zomedica Corp.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Seasonals

ZOM trade ideas

ZOM Breakout Stock AlertBREAKOUT STOCK ALERT $ZOM - Zomedica Corp. Common Shares Initial Alert Price: $2.12 Potential Price: $2.35 Potential Gains: 10.85 Stop Loss Limit: $ As most of you may know, we've been monitoring ZOM over our Pre-Market and Saturday Coffee & Stocks Sessions, and we've been waiting for confirmation that the stock can break back above the $2.12 Price Levels. We will be placing a position on the trade at the $2.12 Entry Level and looking for a minimum 10% Swing while the stock shows momentum of potential finding support above those $2.12 Current Levels of Resistance. We will be looking to retest the $2.35 next to achieve that minimum $2.35 Levels of resistance next and then potentially moving higher back to those $2.91 Levels of Resistance for a potential 40% Swing on the Trade overall as long as the trade meets our expectations. #Breakout #Stocks #Trading #Investing #Alerts #StockMarket #Daily #News #Today
AMEX:ZOMLong
by MyMIWallet
4
ZOM: Should we panic-sell this now?Hello traders and investors! Let’s talk about ZOM today, and do our usual Multi Time Frame Analysis (MTFA)! First, let’s start with the 1h chart. ZOM did a classic Double Top chart pattern at $ 2.91 (black line), and now it is dropping to its support levels. The first support lost, after some fight, was the 21 ema. Then the green line at $ 2.34, and now it is trying to lose the blue line at $ 2.13 as well. Since it is a short-term bear trend, ZOM will keep seeking for lower supports, until one works and holds the price. What’s more, according to the Principle or Polarity , when a support is lost, it is supposed to work as a resistance next, and vice-versa. The green line and the 21 ema could make a strong resistance zone for ZOM in the short-term. Also, keep in mind that ZOM lost the green line by doing a Gap , which is also going to work as a resistance. The fight is not going to be easy for ZOM, but let’s see if the daily chart has something else to tell us: In the mid-term, the trend is clearly bullish, and in a bull trend, pullbacks are expected and seen as opportunities to buy. We have a strong support area between the 21 ema, the black line at $ 1.48 (previous top) and the Gap (yellow rectangle), and ZOM could retest again this area and the trend would still be bullish. What is interesting is the volume , as it increases during upside movements, and decreases when the stock drops or enters in a congestion, meaning that the buy force is stronger than the sell force at this moment. And if you liked this analysis, remember to follow me to keep in touch with my daily updates. And support this idea if it helped you! Let's wait for more confirmation on the charts, before jumping into any conclusion regarding ZOM. Thank you very much,
AMEX:ZOM
by Nathan_The_Finance_Hydra
18
$ZOM Chart patterns. Potential breakoutThis is my prediction of the next uptrend towards Truforma's launch date. The first device from Zomedica. $ZOM is currently in an aggressive upward trend and is likely to continue in this trend. Why? Because you can see in the chart above that $ZOM is currently in its next consolidation just like it was in January. During the making of this post the price has fallen below the resistance. This was also the case in January, but it was immediately corrected the next day (false outbreak). Also the RSI also reveals the new uptrends. Ultimately, I think the idea is that $ZOM will go to $8 and stay there in the next consolidation until they make revenue for the first time. I know that a stock price of $8 entails a huge market cap. But because of the hype of Truforma investors first condone that. I would like to hear feedback from you guys and what you think will happen to the stock in the near future!
AMEX:ZOM
by Patellic
5
ZOM - For the next few days, the price will make an accumulation channel between 2.05 and 2.50. If it breaks the lower limit of the channel, then it will go to the monthly support of 1.83. For short term transactions you can enter buy (only buy, not sell !!) at the lower limit of the channel. If it breaks the lower limit of the channel, then it will go to the monthly support of 1.83. But don't close the position! For long term it is ideal to enter at 1.83 for a rise of 65% to 3.00 where it will make a small pullback and then break the monthly resistance of 3.00 to a value of 4.50 - 5.00 AMEX:ZOM
AMEX:ZOMLong
by premieranalysis
$ZOM Increases Bought Deal Offering of Common Shares to $173.5 MZomedica Corp. Increases Previously Announced Bought Deal Offering of Common Shares to $173.5 Million. today announced that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 91,315,790 common shares of Zomedica, at a price to the public of $1.90 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about February 11, 2021, subject to satisfaction of customary closing conditions. finance.yahoo.com
AMEX:ZOM
by AlenCiken
2
$ZOM could surge 100% due to upcoming launch of TruformaTangible catalyst behind surge is due to the upcoming launch of Truforma , Zomedica’s point-of-care (POC) diagnostic device for the detection of thyroid disease in dogs and cats and adrenal disease in dogs. The platform will hit the market on March 30 , and ahead of the product’s debut, the company has also just nabbed a vital distribution deal. Last week, Zomedica announced an agreement with Miller Veterinary Supply who will distribute Truforma. Miller is the U.S.’s oldest wholesale veterinary distributor and one of the veterinary industry’s fastest growing businesses. The company will be Zomedica’s representative in the eastern and mid-eastern states. Its sales and customer service efforts will be bolstered by sales representatives assigned by Zomedica, which the company is currently recruiting as it prepares for the launch. The pet market has been a prime beneficiary of the pandemic’s stay-at-home mandates and according to the American Pet Products Association, spending in the segment reached a record $99 billion in the U.S. last year. Outlay on diagnostic care in this market is expected to grow to $2.8 billion in 2024 from $1.7 billion in 2019. H.C. Wainwright analyst Swayampakula Ramakanth says that ahead of Truforma’s debut, the agreement “strengthens the commercial machinery.” “We are encouraged by the progress in commercial preparation for the upcoming launch, and accordingly we are raising the probability of launch to 90%, up from 75% previously,” the 5-star analyst said. “Additionally, due to the lower yield of the long-term Treasury note that has resulted in a lower risk-free rate and a lower market risk premium, we have adjusted the discount rate to 6% from 12%.” To this end, Ramakanth boosted his price target on ZOM from $0.3 to $1.2, suggesting upside of an additional 20% from current levels. Needless to say, Ramakanth’s rating stays a Buy. finance.yahoo.com
AMEX:ZOM
by AlenCiken